I was thinking the opposite here. If Prurisol 2B has a 40% PASI 75 on the 300mg arm it is probably worth considerably more than any single Brilacidin indication. In addition there is no royalty tax to be paid out on it. $90M upfront with $100M in milestones + 20% sales on B-OM would allow IPIX to take Prurisol through phase 3 alone.

I could see it playing out your way as well though.

I'd still prefer to see a monster $5B-$7B buyout this year if the Prurisol results are that good. I'm not getting any younger.